BusinessEzutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical TrialBy Nasdaq OMXJan 25, 2018, 12:01 PM UTC
BusinessSummit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical TrialBy Nasdaq OMXNov 20, 2017, 12:00 PM UTC
BusinessSummit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at 15th Action Duchenne International ConferenceBy Nasdaq OMXNov 9, 2017, 12:01 PM UTC
BusinessSummit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne Muscular DystrophyBy Nasdaq OMXSep 25, 2017, 11:00 AM UTC
BusinessSummit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society CongressBy Nasdaq OMXJun 22, 2017, 11:00 AM UTC
BusinessSummit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational ProgressBy Nasdaq OMXDec 15, 2016, 12:00 PM UTC
BusinessSummit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMDBy Nasdaq OMXNov 16, 2016, 12:00 PM UTC
BusinessSummit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXOct 4, 2016, 11:02 AM UTC
